-
公开(公告)号：US06605424B1
公开(公告)日：2003-08-12
申请号：US09568983
申请日：2000-05-11
IPC分类号： C12Q300
CPC分类号： A61K31/715 , A61K31/21 , A61K31/66 , A61K31/675 , A61K38/1787 , G01N33/566 , G01N33/573
摘要： The present invention relates to a method of inhibiting desensitization of a cell to the effects of a compound. The method comprises contacting the cell with an agent capable of inhibiting phosphorylation, by a protein kinase, of a receptor for the compound present on the surface of the cell. The present invention also relates to a method of screening a compound for its ability to inhibit desensitization. The method comprises: i) contacting a receptor specific kinase-containing sample with the compound under conditions such that interaction between receptor specific kinase present in the sample and the compound can occur, and ii) determining the ability of the receptor specific kinase to phosphorylate the receptor for which it is specific.
摘要翻译： 本发明涉及抑制细胞对化合物作用的脱敏的方法。 该方法包括使细胞与能够通过蛋白激酶抑制存在于细胞表面的化合物的受体的磷酸化的试剂接触。 本发明还涉及一种筛选化合物抑制脱敏能力的方法。 该方法包括：i）使受体特异性激酶样品与化合物在使得存在于样品中的受体特异性激酶与化合物之间发生相互作用的条件下接触，以及ii）确定受体特异性激酶使受体磷酸化的能力 它是具体的。
-
2.发明授权Inhibition of agonist-specific desensitization of .beta.2 adrenergic receptors 失效抑制β2肾上腺素能受体激动剂特异性脱敏作用
公开(公告)号：US6096705A
公开(公告)日：2000-08-01
申请号：US38072
申请日：1993-03-29
IPC分类号： A61K31/21 , A61K31/66 , A61K31/675 , A61K38/16 , A61K38/17 , G01N33/566 , G01N33/573 , A61K31/715 , C12N9/12
CPC分类号： A61K31/715 , A61K31/21 , A61K31/66 , A61K31/675 , A61K38/1787 , G01N33/566 , G01N33/573
摘要： The present invention relates to a method of inhibiting desensitization of a cell to the effects of a compound. The method comprises contacting the cell with an agent capable of inhibiting phosphorylation, by a protein kinase, of a receptor for the compound present on the surface of the cell. The present invention also relates to a method of screening a compound for its ability to inhibit desensitization. The method comprises: i) contacting a receptor specific kinase-containing sample with the compound under conditions such that interaction between receptor specific kinase present in the sample and the compound can occur, andii) determining the ability of the receptor specific kinase to phosphorylate the receptor for which it is specific.
摘要翻译： 本发明涉及抑制细胞对化合物作用的脱敏的方法。 该方法包括使细胞与能够通过蛋白激酶抑制存在于细胞表面的化合物的受体的磷酸化的试剂接触。 本发明还涉及一种筛选化合物抑制脱敏能力的方法。 该方法包括：i）使受体特异性激酶样品与化合物在使得存在于样品中的受体特异性激酶与化合物之间发生相互作用的条件下接触，以及ii）确定受体特异性激酶磷酸化的能力 受体是特异性的。
-
公开(公告)号：US08889425B2
公开(公告)日：2014-11-18
申请号：US10580027
申请日：2004-11-26
IPC分类号： G01N33/533 , G01N33/52 , A61K49/00 , C07K19/00 , C07K14/47 , C07K14/435 , C12Q1/44 , G01N33/573 , C12Q1/527 , G01N33/542
CPC分类号： G01N33/533 , A61K49/0017 , C07K14/43595 , C07K14/4702 , C07K2319/20 , C12Q1/44 , C12Q1/527 , G01N33/542 , G01N33/5735 , G01N2500/02 , G01N2500/04
摘要： Described is a chimeric peptide, comprising, in order, (a) a first detectable label (b) a cAMP binding moiety having only one cAMP binding site and (c) a second detectable label least two detectable labels is describe. The chimeric peptide is useful for direct determination of cAMP concentration in vitro and/or in vivo. Also described are nucleic acids encoding the chimeric peptide, methods of making and modifying the chimeric peptide, a method for determining the cAMP concentration, and kits.
摘要翻译： 描述了嵌合肽，其顺序包含（a）第一可检测标记（b）仅具有一个cAMP结合位点的cAMP结合部分和（c）第二可检测标记物至少两个可检测标记。 嵌合肽可用于体外和/或体内直接测定cAMP浓度。 还描述了编码嵌合肽的核酸，制备和修饰嵌合肽的方法，确定cAMP浓度的方法和试剂盒。
-
4.发明申请BINDING COMPOUNDS TO HUMAN Beta 1-ADRENORECEPTOR (Beta 1-AR) AND THEIR USE IN MEASUREMENT OF AUTO-ANTI- Beta 1-AR ANTIBODIES 审中-公开人β-ADRENORECEPTOR（Beta 1-AR）的结合化合物及其在自身抗体测定中的用途 - 1-AR抗体公开(公告)号：US20140273015A1
公开(公告)日：2014-09-18
申请号：US14124649
申请日：2012-06-06
申请人： Hans-Peter Holthoff , Martin Ungerer , Stefan Zeibig , Martin J. Lohse , Roland Jahns , Valerie Jahns
发明人： Hans-Peter Holthoff , Martin Ungerer , Stefan Zeibig , Martin J. Lohse , Roland Jahns , Valerie Jahns
CPC分类号： G01N33/74 , C07K16/286 , C07K16/2869 , C07K2317/34 , C07K2317/92 , G01N33/6893 , G01N33/9433 , G01N2800/325
摘要： The present disclosure relates to binding compounds/antibodies that bind to the second extracellular loop of the human β1-adrenoreceptor (β1-AR-ECII) that are produced by/obtainable from a host cell/hybridoma with a deposit number selected from the group consisting of DSM ACC3121, DSM ACC3174, DSM ACC3175, DSM ACC3176 and DSM AC-C3177. The binding compounds/antibodies are particularly useful in determination of auto-anti-β1-AR antibodies in an in vitro cell based assay system in order to characterize and to identify auto-antibodies directed against the β1-AR-ECII in a biological sample. Further aspects of the disclosure are nucleic acid molecules encoding said binding compounds/antibodies, vectors, host cells, methods for producing the binding compounds/antibodies of the disclosure as well as a kit comprising the binding compounds/antibodies of the present disclosure.
摘要翻译： 本公开涉及结合化合物/抗体，所述化合物/抗体结合由具有选择的保藏号的宿主细胞/杂交瘤产生/可获得的人β-肾上腺素受体（＆bgr; 1-AR-ECII）的第二细胞外环 来自由DSM ACC3121，DSM ACC3174，DSM ACC3175，DSM ACC3176和DSM AC-C3177组成的组。 结合化合物/抗体特别可用于在基于体外细胞的测定系统中测定自身抗体和抗体1-AR抗体，以鉴定和鉴定针对1-AR-ECII的自身抗体 生物样品。 本公开的另外方面是编码所述结合化合物/抗体，载体，宿主细胞的核酸分子，用于产生本公开的结合化合物/抗体的方法以及包含本公开内容的结合化合物/抗体的试剂盒。
-
公开(公告)号：US08796428B2
公开(公告)日：2014-08-05
申请号：US13130495
申请日：2009-11-26
申请人： Martin J. Lohse , Kristina Lorenz
发明人： Martin J. Lohse , Kristina Lorenz
CPC分类号： C07K16/40 , A01K67/0275 , A01K2217/052 , A01K2217/056 , A01K2227/105 , A01K2267/0375 , C07K16/44 , C12N9/1205 , G01N33/573 , G01N33/6893 , G01N2800/32
摘要： The invention relates to an antibody specific to Erk1/2 phosphorylated at Thr188 and a method for producing the same. The invention also relates to an in vitro method for determining the presence of phosphorylated Erk1/2 in a sample using the antibody of the invention. Therefore, the invention also comprises an assay for diagnosing a heart disease in vitro comprising the antibody of the invention and certain uses of the antibody. Moreover the invention relates to a peptide used to produce the antibody.
摘要翻译： 本发明涉及在Thr188上磷酸化的Erk1 / 2特异性抗体及其制备方法。 本发明还涉及使用本发明的抗体测定样品中磷酸化Erk1 / 2的存在的体外方法。 因此，本发明还包括用于诊断体外心脏病的测定法，其包含本发明的抗体和抗体的某些用途。 此外，本发明涉及用于产生抗体的肽。
-
公开(公告)号：US08716030B2
公开(公告)日：2014-05-06
申请号：US13449966
申请日：2012-04-18
申请人： Roland Jahns , Valérie Jahns , Martin J. Lohse , Dieter Palm
发明人： Roland Jahns , Valérie Jahns , Martin J. Lohse , Dieter Palm
IPC分类号： G01N33/564
CPC分类号： C07K14/70571 , C07K7/64
摘要： Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.
摘要翻译： 本发明的实施方案提供了用于检测和/或抑制抗 - 1-肾上腺素能受体抗体的新型肽。 某些实施方案涉及环肽和/或线性肽的使用。 在其它实施方案中，本发明涉及用于诊断和/或药物组合物的新型肽。 一些实施方案涉及诊断和/或治疗心脏病症。 本发明的心脏病可以涉及感染性心脏病，非传染性心脏病，缺血性心脏病，非缺血性心脏病，炎性心脏病，心肌炎，心脏扩张，特发性心肌病，特发性扩张型心肌病，免疫性心肌病，心力衰竭 ，以及任何心律失常症状。
-
7.发明授权公开(公告)号：US08715682B2
公开(公告)日：2014-05-06
申请号：US13449984
申请日：2012-04-18
申请人： Roland Jahns , Valérie Jahns , Martin J. Lohse , Dieter Palm
发明人： Roland Jahns , Valérie Jahns , Martin J. Lohse , Dieter Palm
IPC分类号： A61K38/12 , C07K7/52 , G01N33/564
CPC分类号： C07K14/70571 , C07K7/64
摘要： Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.
摘要翻译： 本发明的实施方案提供了用于检测和/或抑制抗 - 1-肾上腺素能受体抗体的新型肽。 某些实施方案涉及环肽和/或线性肽的使用。 在其它实施方案中，本发明涉及用于诊断和/或药物组合物的新型肽。 一些实施方案涉及诊断和/或治疗心脏病症。 本发明的心脏病可以涉及感染性心脏病，非传染性心脏病，缺血性心脏病，非缺血性心脏病，炎性心脏病，心肌炎，心脏扩张，特发性心肌病，特发性扩张型心肌病，免疫性心肌病，心力衰竭 ，以及任何心律失常症状。
-
8.发明申请公开(公告)号：US20090215675A1
公开(公告)日：2009-08-27
申请号：US11910258
申请日：2006-03-31
申请人： Roland Jahns , Valérie Jahns , Martin J. Lohse , Dieter Palm
发明人： Roland Jahns , Valérie Jahns , Martin J. Lohse , Dieter Palm
IPC分类号： C07K7/64 , C07K7/06 , C07K7/08 , C07K14/00 , A61K38/08 , A61K38/12 , A61K38/10 , A61K38/16 , G01N33/53 , A61P9/00
CPC分类号： C07K14/70571 , C07K7/64
摘要： The present invention is related to a peptide selected from the group comprising a) a cyclic peptide of formula (I): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-x-x-x-Pro-x-Cys-Cys-xk-GIn), (I) whereby k is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably k=6; b) a cyclic peptide of formula (II): Cyclo(Ala-x-x-Trp-x-x-Gly-x-Phe-x-Cys-xh-Gln), (II) whereby h is any integer from 0 to 2, preferably 1 or 2; c) a cyclic peptide of formula (III): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-xj-Cys-x-x-x-Pro-x-Cys-Cys-xi-Gln); (HI) whereby j is any integer from 0 to 4, preferably j=4; whereby i is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably i−6; and d) a peptide of formula (IV): Ala-x1-Cys-xm-Cys-x-x-x-Pro-x-Cys-Cys-xn-Gln, (IV) whereby 1 is any integer from 0 to 9, preferably any integer from 1 to 9, more preferably n=9; whereby m is any integer from 0 to 4, preferably any integer from 1 to 4, more preferably m=4; whereby n is any integer from O to 6, preferably any integer from 1 to 6, more preferably n=6; whereby x is any amino acid, preferably any naturally occurring amino acid, more preferably any naturally occurring L-amino acid.
摘要翻译： 本发明涉及一种选自以下的肽：a）式（I）的环状肽：Cyclo（Ala-xxxxxxxxx-Cys-xxx-Pro-x-Cys-Cys-xk-Gln），（I） 其中k是0至6的任何整数，优选1至6的任何整数，更优选k = 6; b）式（II）的环状肽：环（Ala-xx-Trp-xx-Gly-x-Phe-x-Cys-xh-Gln），（II），其中h是0至2的任何整数， 1或2; c）式（III）的环肽：环（Ala-x-x-x-x-x-x-x-x-x-x-Pro-x-Cys-Cys-xi-Gln） （HI），其中j是0至4的任何整数，优选j = 4; 其中i是0至6的整数，优选1至6的任何整数，更优选i-6; 和d）式（IV）的肽：Ala-x1-Cys-xm-Cys-xxx-Pro-x-Cys-Cys-xn-Gln，（IV）其中1是0至9的任何整数， 1〜9的整数，更优选n = 9; 其中m是0至4的整数，优选1至4的任何整数，更优选m = 4; 其中n是0至6的整数，优选1至6的任何整数，更优选n = 6; 其中x是任何氨基酸，优选任何天然存在的氨基酸，更优选任何天然存在的L-氨基酸。
-
公开(公告)号：US20080286760A1
公开(公告)日：2008-11-20
申请号：US10580027
申请日：2004-11-26
IPC分类号： C12Q1/68 , C07K7/00 , C12N9/02 , C07K14/00 , C12N15/11 , C12N15/00 , C12N5/06 , C12N1/14 , C12N5/04 , C12N1/20 , A01K67/027 , C12P21/06 , G01N33/566
CPC分类号： G01N33/533 , A61K49/0017 , C07K14/43595 , C07K14/4702 , C07K2319/20 , C12Q1/44 , C12Q1/527 , G01N33/542 , G01N33/5735 , G01N2500/02 , G01N2500/04
摘要： The present invention relates to a chimeric peptide, comprising a cAMP binding moiety having only one cAMP binding site and at least two detectable labels, whereby the first of said two detectable labels is located at the carboxy terminus and the second of said two detectable labels is located at the amino terminus of said cAMP binding moiety. Said chimeric peptide of the invention is particularly useful in/for direct determination of cAMP concentrations) in vitro and/or in vivo. Furthermore, nucleic acid molecules encoding said chimeric proteins are described as well as vectors and host cells comprising the same. The present invention also provides methods for producing the chimeric protein of the invention and methods for identification and screening of molecules or compounds which are capable of modifying cAMP binding to the chimeric peptide of the invention or the biological and/or pharmacological function of adenylyl cyclases or phosphodiesterases. In addition, a method for cAMP determination in a sample and a method for the detection of cAMP in the living cell or tissue is described. Finally, a kit comprising the compounds of the present invention is disclosed.
摘要翻译： 本发明涉及嵌合肽，其包含仅具有一个cAMP结合位点和至少两个可检测标记的cAMP结合部分，其中所述两个可检测标记中的第一个位于羧基末端，并且所述两个可检测标记中的第二个位于 位于所述cAMP结合部分的氨基末端。 本发明的所述嵌合肽在体外和/或体内特别可用于/用于cAMP浓度的直接测定。 此外，还描述了编码所述嵌合蛋白质的核酸分子以及包含其的载体和宿主细胞。 本发明还提供了用于产生本发明的嵌合蛋白质的方法和用于鉴定和筛选能够修饰cAMP与本发明的嵌合肽结合的分子或化合物的方法或腺苷酸环化酶的生物学和/或药理学功能 磷酸二酯酶。 此外，描述了用于样品中cAMP测定的方法和用于检测活细胞或组织中cAMP的方法。 最后，公开了包含本发明化合物的试剂盒。
-
10.发明授权Mutant double cyclized receptor peptides inhibiting β1-adrenoceptor antibodies 有权突变双环化受体肽抑制和1-肾上腺素受体抗体公开(公告)号：US09062095B2
公开(公告)日：2015-06-23
申请号：US12733347
申请日：2008-08-22
CPC分类号： C07K7/64 , A61K38/00 , G01N33/6854
摘要： The present invention relates to novel β-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-β-adrenergic receptor antibodies like anti-β-adrenergic receptor antibodies.
摘要翻译： 本发明涉及可以形成这些环肽突变体的线性肽和编码这些环肽突变体和线性肽的核酸分子的仅包含两个能够形成分子内连接的半胱氨酸残基的新颖的-b同源的环肽突变体。 此外，提供了包含所述核酸分子的载体和重组宿主细胞以及用于制备所公开的环肽突变体的方法。 还提供了包含本发明的肽，核酸分子，载体或宿主细胞的组合物。 本发明还涉及利用本发明的肽的治疗和诊断手段，方法和用途以及用于检测抗 - 抗 - 肾上腺素能受体抗体（如抗 - 肾上腺素能受体抗体）的手段，方法和用途。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.028 秒)
